Fujifilm to Set Up iPS Cell Production Facility in U.S.

Economy

Tokyo, Dec. 20 (Jiji Press)--Japan's Fujifilm Corp. said Thursday it will spend some 2.5 billion yen to set up in the United States a facility to produce induced pluripotent stem, or iPS, cells for treatment purposes.

The company, under the wing of Fujifilm Holdings Corp. <4901>, hopes to have the facility start operating during fiscal 2019, which begins in April next year.

The facility will be built in the vicinity of a regenerative medicine unit of Fujifilm in Wisconsin. The unit, which has been using university equipment to produce iPS cells for research into disease treatment and drug development, will have its own production facility with an eye to launching commercial production in the future.

Fujifilm has been stepping up operations in the field of regenerative medicine using iPS cells, which can develop into almost any type of cell and are expected to be utilized for treating cancer, Parkinson's disease and other illnesses.

The company already has an iPS cell production facility in Japan.

[Copyright The Jiji Press, Ltd.]

Jiji Press